Hovinga, K. E., McCrea, H. J., Brennan, C., Huse, J. T., Zheng, J., Esquenazi, Y., . . . Tabar, V. (2019). EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
Lua i Stíl Chicago (17ú heag.)Hovinga, Koos E., Heather J. McCrea, Cameron Brennan, Jason T. Huse, Junting Zheng, Yoshua Esquenazi, Katherine S. Panageas, agus Viviane Tabar. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.
Lua MLA (9ú heag.)Hovinga, Koos E., et al. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.
Rabhadh: Seans nach mbeach na luanna seo go hiomlán cruinn i ngach uile chás.